


RealRate

PHARMACEUTICAL 2022











PHARMACEUTICAL 2022



CORCEPT THERAPEUTICS INC Rank 4 of 466



The relative strengths and weaknesses of CORCEPT THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CORCEPT THERAPEUTICS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 141% points. The greatest weakness of CORCEPT THERAPEUTICS INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 8.9% points.

The company's Economic Capital Ratio, given in the ranking table, is 322%, being 244% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	266,463
Cost of Goods Sold	5,281
Intangible Assets	0
Liabilities, Current	47,541
Liabilities, Non-Current	0
Other Assets	156,291
Other Compr. Net Income	-642
Other Expenses	12,494
Other Liabilities	409
Other Net Income	529
Other Revenues	365,978
Property and Equipment	1,002
Research and Development	113,864
Selling, General and Administrative Expense	122,356

Output Variable	Value in 1000 USD
Assets	423,756
Liabilities	47,950
Expenses	253,995
Revenues	365,978
Stockholders Equity	375,806
Net Income	112,512
Comprehensive Net Income	112,191
Economic Capital Ratio	322%

